Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)

被引：7

作者：

Loibl, S. ^{[1
]}

Loirat, D. ^{[2
,3
]}

Tolaney, S. M. ^{[4
]}

Punie, K. ^{[5
,6
]}

Oliveira, M. ^{[7
,8
,9
]}

Rugo, H. S. ^{[10
]}

Bardia, A. ^{[11
]}

Hurvitz, S. A. ^{[12
]}

Brufsky, A. ^{[13
,14
]}

Kalinsky, K. ^{[15
]}

Cortes, J. ^{[16
]}

O'Shaughnessy, J. ^{[17
]}

Dieras, V. C. ^{[18
]}

Carey, L. A. ^{[19
]}

Gianni, L. ^{[20
]}

Gharaibeh, M. ^{[21
]}

Moore, L. ^{[21
]}

Shi, L. ^{[22
]}

Piccart, M. ^{[23
,24
]}

机构：

[1] Hamatol Onkol Gemeinschaftspraxis Bethanien Krank, Dept Med & Res, Frankfurt, Germany

[2] Inst Curie, Med Oncol Dept, Paris, France

[3] Inst Curie, D3i, Paris, France

[4] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[5] Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium

[6] Univ Hosp Leuven, Leuven Canc Inst, Multidisciplinary Breast Ctr, Leuven, Belgium

[7] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[8] Vall dHebron Univ Hosp, Breast Canc Grp, Barcelona, Spain

[9] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[10] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[11] Harvard Med Sch, Dept Hematol & Oncol, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA

[12] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Med Oncol,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA

[13] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Div Hematol Oncol, Pittsburgh, PA 15213 USA

[14] Univ Pittsburgh, Hillman Canc Ctr, Med Ctr, Pittsburgh, PA USA

[15] Columbia Univ Irving Med Ctr, Dept Med, New York, NY USA

[16] Quiron Grp, Med Oncol Dept, Int Breast Canc Ctr, Barcelona, Spain

[17] Texas Oncol Baylor A Charles Sammons Canc Ctr, Med Oncol, Dallas, TX USA

[18] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France

[19] Univ N Carolina, Med Hematol Oncol Div, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[20] Gianni Bonadonna Fdn, Med Oncol, Milan, Italy

[21] Gilead Sci Inc, Dept Global Value & Access, Morris Plains, NJ USA

[22] Evidera PPD, Dept Evidence Synth Modeling & Commun EMC, Waltham, MA USA

[23] Inst Jules Bordet, Med Oncol Dept, Brussels, Belgium

[24] Univ Libre Bruxelles, Brussels, Belgium

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.540

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

257P

引用

页码：S472 / S473

页数：2

共 50 条

[11] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A.
Hurvitz, S. A.
Tolaney, S. M.
Loirat, D.
Punie, K.
Oliveira, M.
Brufsky, A.
Sardesai, S. D.
Kalinsky, K.
Zelnak, A. B.
Weaver, R.
Traina, T.
Dalenc, F.
Aftimos, P.
Lynce, F.
Diab, S.
Cortes, J.
O'Shaughnessy, J.
Dieras, V
Ferrario, C.
Schmid, P.
Carey, L. A.
Gianni, L.
Piccart, M. J.
Loibl, S.
Goldenberg, D. M.
Hong, Q.
Olivo, M. S.
Itri, L. M.
Rugo, H. S.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
[12] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
Schoellmann, Claudia
BREAST CARE, 2022, 17 (01)
[13] Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
Sathe, A. G.
Singh, I.
Singh, P.
Diderichsen, P.
Wang, X.
Chang, P.
Phan, S-C.
Girish, S.
Othman, A. A.
ANNALS OF ONCOLOGY, 2022, 33 : S214 - S214
[14] SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)
Cona, M. S.
Ruggieri, L.
Artale, S. A. A.
Catania, G.
D'Auria, G.
Gallerani, E.
Villa, F.
Gambaro, A.
Chirco, A.
Giordano, M.
Pistelli, M.
Verderame, F.
Bramati, A.
Stani, S. C.
Vici, P.
Meattini, I.
Tagliaferri, B.
Tedesco, B.
Amato, O.
La Verde, N. M.
ANNALS OF ONCOLOGY, 2024, 35 : S381 - S382
[15] Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
Loibl, Sibylle
Tolaney, Sara M.
Punie, Kevin
Oliveira, Mafalda
Rugo, Hope S.
Bardia, Aditya
Hurvitz, Sara A.
Brufsky, Adam
Kalinsky, Kevin M.
Cortes, Javier
O'Shaughnessy, Joyce
Carey, Lisa A.
Gianni, Luca
Dieras, Veronique
Shi, Ling
Gharaibeh, Mahdi
Preger, Luciana
Moore, Lee
Phan, See
Piccart, Martine
CANCER RESEARCH, 2022, 82 (04)
[16] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
Schreiber, Anna R.
Andress, Michelle
Diamond, Jennifer R.
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
[17] Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
Singh, Indrajeet
Sathe, Abhishek G.
Singh, Pratap
Diderichsen, Paul M.
Fauchet, Floris
Maringwa, John
Pierrillas, Philippe
Phan, See-Chun
Girish, Sandhya
Othman, Ahmed A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[18] Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results
Seneviratne, Lasika C.
Harnden, Kathleen Kiernan
Blau, Sibel
Danso, Michael A.
Berz, David
Guaqueta, Delia Constanza
Schwerkoske, John F.
O'Shaughnessy, Joyce
Patt, Debra A.
Bardia, Aditya
McCann, Kelly Elizabeth
Beelen, Andrew Paul
Zhang, Jingshan
Yi, John S.
Hurvitz, Sara A.
Mardones, Mabel Alejandra
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[19] Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study
Hurvitz, S. A.
Bardia, A.
Punie, K.
Kalinsky, K.
Cortes, J.
O'Shaughnessy, J.
Carey, L. A.
Rugo, H. S.
Yoon, O. K.
Pan, Y.
Delaney, R. J.
Hofsess, S.
Hodgkins, P.
Phan, S-C.
Dieras, V.
ANNALS OF ONCOLOGY, 2022, 33 : S200 - S201
[20] Sacituzumab govitecan in triple-negative breast cancer
de Nonneville, Alexandre
Goncalves, Anthony
Mamessier, Emilie
Bertucci, Francois
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)

← 1 2 3 4 5 →